Are biosimilars for pemphigus safe?-Reference-Cited by-同舟云学术

Are biosimilars for pemphigus safe?

Published:2021-05-02 Issue:5 Volume:46 Page:942-943
ISSN:0307-6938
Container-title:Clinical and Experimental Dermatology
language:en
Short-container-title:Clin Exp Dermatol

Author:

Ho G.¹^ORCID,Sheriff T.¹²^ORCID,Doria‐Ruiz M.²,Loh Y.³,Murrell D. F.¹²⁴^ORCID

Affiliation:

1. Departments of Dermatology St George Hospital Sydney NSW Australia

2. University of New South Wales Sydney NSW Australia

3. Cancer Care Centre, St George Hospital Sydney NSW Australia

4. The George Institute for Global Health Sydney Australia

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ced.14610

Reference5 articles.

1. Diagnosis and management of pemphigus: Recommendations of an international panel of experts

2. Australian Government Department of Health.Rituximab: solution for I.V. infusion 100 mg in 10 mL 2 vials solution for I.V. infusion 500 mg in 50 mL 1 vial; Riximyo®. 2018. Avaiable at:https://www.pbs.gov.au/pbs/industry/listing/elements/pbac‐meetings/psd/2018‐03/Rituximab‐infusion‐psd‐march‐2018(accessed 11 February 2021).

3. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial

4. Efficacy and safety of biosimilar rituximab in patients with pemphigus vulgaris: a prospective observational study

5. Effectiveness and safety analysis of rituximab in 146 Indian pemphigus patients: A retrospective single-center review of up to 68 months follow-up

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rituximab;Reactions Weekly;2021-07

2. Pustular eruption after biosimilar rituximab infusion: report of acute generalized exanthematous pustulosis in two patients with pemphigus;International Journal of Dermatology;2021-06-22